Citations

Clear

2303 citation(s) found for "Yu, Edward".

Disparities across the pediatric epilepsy surgery journey: Referral, recommendation, and completion from a national consortium
Berl, Madison M. , Wagner, Janelle L. , Caraway, Avery Robert, Loblein, Hayley , Novotny, Edward J. , Patrick, Kristina E. , Ostendorf, Adam P. , Alexander, Allyson , Eschbach, Krista , Depositario‐Cabacar, Dewi F., Vu, Thuy‐Anh , Karia, Samir R., Romanowski, Erin Fedak , Bolton, Jeffrey , Ailion, Alyssa , Tatachar, Priyamvada, Pichon, Pilar, Shrey, Daniel W. , Singh, Rani K., Lin, Jenny, Koop, Jennifer I. , Gonzalez‐Giraldo, Ernesto, Auguste, Kurtis I. , Bernardo, Danilo , Ciliberto, Michael A. , Reddy, Shilpa B. , Ganesh, Abhinaya, Arredondo, Kristen H. , Nangia, Srishti, Samanta, Debopam, Marashly, Ahmad , Armstrong, Dallas , Perry, M. Scott, Workgroup, the PERC Surgery, Caraway, Avery R. , Wagner, Janelle , Caraway, Avery Robert , Patrick, Kristina E , Alexander, Allyson L , Eschbach, Krista , Depositario Cabacar, Dewi Frances , Oluigbo, Chima O , Karia, Samir , Karakas, Cemal , Wong-Kisiel, Lily C. , Fedak Romanowski, Erin , McNamara, Nancy A , Bolton, Jeffrey Brian , Ailion, Alyssa , Tatachar, Priyamvada , Pichon, Pilar D , Shrey, Daniel W , Coryell, Jason , Koop, Jennifer I , Gonzalez-Giraldo, Ernesto , Auguste, Kurtis I , Bernardo, Danilo , Ciliberto, Michael A , Reddy, Shilpa B , Ganesh, Abhinaya , Arredondo, Kristen H , Grinspan, Zachary , Nangia, Srishti , Samanta, Debopam , Armstrong, Dallas Michael , Perry, Michael Scott , Berl, Madison , Novotny, Edward J , Loblein, Hayley, Depositario‐Cabacar, Dewi, Oluigbo, Chima , Karia, Samir , Karakas, Cemal , Wong‐Kisiel, Lily C. , McNamara, Nancy , Tatachar, Priyamvada , Coryell, Jason , Gonzalez‐Giraldo, Ernesto , Grinspan, Zachary M. , Samanta, Debopam

Mayo Clinic

Epilepsia | January 24, 2026 | Volume: 67 | Issue: 4 | Pages: 1601-1613

10.1002/epi.70060 | PMID 41579031 Get It

Abstract Objective Despite being safe and effective, surgery for pediatric epilepsy is underutilized. Social determinants of health (SDoH) are important to consider when examining this treatment gap. This study examined the potential systemic inequities at three different stages in the journey toward epilepsy surgery across the Pediatric Epilepsy Research Consortium (PERC). Methods Any youth in the PERC prospective surgery database (≤18 years) was eligible and included if sociodemographic factors were also available. We examined if there were differences in disparity factors in: (1) referral to Phase I evaluation, (2) offering of surgery, and (3) completion of surgery. Results Of 1309 patients, the majority were male (53%, p = .04), White (82.2%, p < .001), not Hispanic or Latino (84.3%, p < .001), and privately insured (56.3%, p < .001). Of the youth who were offered surgical treatment ( n = 1103, 84.3%), there were no significant differences in race/ethnicity or sex. Those with a structural lesion were more likely to be offered surgery, and historically marginalized youth were more likely to have a lesion. Of patients who completed surgery ( n = 927, 84.0%), White patients were 1.88 times (95% confidence interval [CI]: 1.14–3.04) more likely than Black patients to complete surgery ( p = .01). Significance Youth who began surgery evaluation are not representative of the demographics of those with epilepsy in the United States, with greater representation of White, non‐Hispanic male individuals. In addition, youth who began surgery evaluation disproportionally have private insurance. At the next stage of offering surgery, there were no differences based on SDoH. However, there is evidence that underrepresented youth that were magnetic resonance negative were less likely to be referred for surgical workup and that Black youth were less likely to undergo surgery. Therefore, efforts to provide equitable opportunity for all youth with refractory epilepsy should be concentrated at the referral for surgery evaluation point of care; however, additional efforts are also needed at later stages.
Noise in the diagnosis of epilepsy by experts
Nascimento, Fábio A. , McLaren, John R. , Zhao, Wei, Katyal, Roohi , Sheikh, Irfan S., Kong, Wan Yee , Aljaafari, Danah , Barot, Nirav, Benbadis, Selim, Friedman, Daniel, Gavvala, Jay R. , Halford, Jonathan, Hogan, R. Edward, Kaplan, Peter W., Matthews, Rebecca, O'Donovan, Cormac, Stefan, Rampp, Sirven, Joseph I , Tatum, William O. , Williams, Jonathan, Yacubian, Elza Márcia, Yuan, Doyle, Beniczky, Sándor, Sibony, Olivier, Westover, M. Brandon, Benbadis, Selim R. , Westover, M. Brandon , McLaren, John R. , Benbadis, S , Karakis, Ioannis , Schuele, Stephan , Sirven, Joseph, Tatum, William O , Beniczky, Sándor , Westover, M Brandon , Gavvala, Jay R , Nascimento, Fábio A , Barot, Nirav, Friedman, Daniel , Halford, Jonathan J. , Hogan, R Edward , Kaplan, Peter W., Karakis, Ioannis , Maheshwari, Atul , Matthews, Rebecca, O'Donovan, Cormac, Williams, Jonathan, Yacubian, Elza Márcia, Yuan, Doyle , Sibony, Olivier

Mayo Clinic

Epileptic Disorders | January 20, 2026 | Volume: 28 | Issue: 2 | Pages: 457-469

10.1002/epd2.70181 | PMID 41556879 Get It

Abstract Objective To measure the relative levels of signal and noise in expert diagnosis of epilepsy. Methods Twenty multinational epileptologists independently reviewed 50 vignettes of adult and pediatric patients presenting with suspected seizure(s) on two separate occasions with a ≥30‐day washout period. Experts provided a diagnosis of epilepsy or non‐epilepsy based on clinical information and, if requested, routine EEG and neuroimaging data. Cases had an established clinical diagnosis of epilepsy or non‐epilepsy based on capture of habitual paroxysmal events on video‐EEG or long‐term clinical follow‐up. Experts' judgments were analyzed to decompose variability into different sources: signal (objective differences between cases), level noise (experts' bias toward over/under‐diagnosis), pattern noise (experts' idiosyncratic reactions to specific case features), and occasion noise (inconsistency across occasions). Results The probability of an expert making a different diagnosis for a given case on two different occasions was 16%. The probability of two different experts making a different diagnosis for the same case was 26%. Signal (case “difficulty”) accounted for 66–69% of total variation, with 31–34% attributable to noise. Level noise was the largest contributor in the absence of EEG/neuroimaging results (23%), while pattern noise dominated when test results were available (24%). Occasion noise contributed relatively little (1%) but was still sufficient to cause diagnostic reversals in 16–22% between occasions. Significance The degree of noise in expert diagnosis of epilepsy is substantial, stemming primarily from physicians' idiosyncratic interpretations of case features and variable dispositions toward over‐ or under‐diagnosis. Strategies to improve reliability are needed, including standardized data collection protocols and structured decision algorithms. For “difficult cases,” where expert reliability and accuracy are lowest, our findings support current clinical practice which favors early referral for video‐EEG monitoring over reliance on diagnostic anchoring. This diagnostic pathway may become more accessible with advances in EEG technology (e.g., wearable devices) and artificial intelligence.
Transulnarversus transradial artery access in patients undergoing cardiac procedures: a systematic review and meta-analysis
Al-Shamari, Mohamed Falah Abdullah, Zreigh, Sofian , Waqas, Daniya, Htet, Yamin , Iqbal, Iqra, Ashraf, Efrah, Javaid, Sana, Farooq, Imshal, Feyisa, Milikyas Abera, Rehman, Mohammad Ebad Ur , Alsubari, Asma’a Munasar Ali, Nashwan, Abdulqadir J. , Mohammad, Ameen Mosa , Ahmad, Adeel, Rehman, Wajeeh Ur , Ahmed, Raheel , Munasar Ali Alsubari, Asma'a , Mosa, Ahmed A. , Htet, Yamin, Iqbal, Iqra, Cheema, Huzaifa Ahmad

Mayo Clinic

Annals of Medicine & Surgery | January 20, 2026 | Volume: 88 | Issue: 2 | Pages: 1806-1814

10.1097/ms9.0000000000004696 | PMID 41675798 Get It

Background: Transradial artery access (TRA) is the favored approach for percutaneous coronary intervention (PCI) and coronary angiography (CAG). However, transulnar artery access (TUA) has emerged as an alternative, particularly when TRA is not feasible. This systematic review and meta-analysis aims to compare the efficacy and safety of TUA versus TRA in patients undergoing PCI and CAG. Methods: From inception to August 2025, a systematic search of electronic databases was conducted. Data were synthesized using a random-effects model, and heterogeneity was assessed using the I 2 statistic. Results: Nine RCTs involving 6089 patients were included. Meta-analysis revealed no significant difference in procedural success between TUA and TRA (RR: 0.93, 95% CI: 0.82–1.06, P = 0.28, I 2 = 99%). Similarly, puncture success rates were comparable (RR: 0.95, 95% CI: 0.91–1.00, P = 0.06, I 2 = 83%). Secondary outcomes showed no significant differences in puncture attempts or hematoma incidence, but TRA was associated with a shorter procedure time (MD: 0.89, 95% CI: 0.27–1.50, P = 0.005). Conclusion: TUA provides a viable alternative to TRA, with similar success rates and complication profiles. However, TRA remains superior in terms of procedure time. Further large-scale RCTs are warranted to confirm these findings and refine clinical guidelines.
IOlBD evidence-based consensus on the use of artificial intelligence for assessment of endoscopic and histologic endpoints in clinical trials of inflammatory bowel disease
Dignass, Axel, Narula, Neeraj, Pratap, Krishan , Danese, Silvio, Iacucci, Marietta, Jairath, Vipul, Loftus, Edward V, Magro, F, Mantzaris, Gerassimos J. , Peyrin-Biroulet, Laurent, Rubin, David T, Sands, Bruce E, Turner, Dan, Reinisch, Walter, Loftus, Edward V. , Dignass, Axel , Narula, Neeraj , Danese, Silvio , Iacucci, Marietta , Loftus, Edward V , Mantzaris, Gerassimos , Peyrin-Biroulet, Laurent , Rubin, David T , Turner, Dan , Reinisch, Walter , Narula, Neeraj , Danese, Silvio , Dotan, Iris , Iacucci, Marietta , Jairath, Vipul , Magro, Fernando, Peyrin‐Biroulet, Laurent , Rubin, David T. , Sands, Bruce E , Turner, Dan

Mayo Clinic

Journal of Crohn's and Colitis | January 18, 2026 | Volume: 20 | Issue: 3 | Pages: No page available

10.1093/ecco-jcc/jjag007 | PMID 41802119 Get It

Abstract Background & Aims Central reading of endoscopy and histopathology is the current standard for disease activity assessment in inflammatory bowel disease (IBD) clinical trials but is limited by interreader and intrareader variability, operational delays, and cost. Artificial intelligence (AI) and machine learning (ML) offer the potential to improve accuracy, efficiency, and reproducibility. The International Organization for the Study of IBD (IOIBD) developed consensus statements on AI/ML use for endoscopic and histologic endpoint assessment in IBD trials. Methods As part of the IOIBD endpoints cluster initiative, a narrative, evidence-informed review with literature searches of Medline and Embase (January 2018-February 2025) identified studies applying AI/ML to endoscopy or histology in IBD. Relevant evidence informed 36 survey statements formulated by a steering committee. Seventy-two IOIBD members were invited to vote online; consensus required ≥80% agreement (score: 7-10 on a 10-point scale). Results Forty-five members completed the survey. Consensus was reached for 28 statements related to endoscopy, pathology, and trial design. Experts agreed that AI-based central reading could improve diagnostic accuracy, expedite processes, reduce costs, and enhance reproducibility. Combining human and AI assessments was favored over AI replacement. The key limitations identified included insufficient validation, generalizability concerns, and dependence on human-annotated training datasets. Conclusions This IOIBD consensus supports the integration of AI/ML into central reading for IBD clinical trials to improve objectivity, efficiency, and consistency, while maintaining human oversight. Further research should address validation, regulatory frameworks, and multimodal integration to enable broader adoption in both trials and clinical practice.
Sirolimus-Coated Versus Paclitaxel-Coated Balloons for Coronary Artery Disease: A Grade Assessed Systematic Review and Meta-Analysis
Sajjad, Fatima , Khattak, Asad Iqbal , Farhan, Kanza, Arshad, Ayesha , Afridi, Abdullah, Shahid, Iqra, Imtiaz, Zeeshan , Naveed, Hammad, Alam, Umama , Henna, Fathimathul, Riaz, Zoya, Khattak, Fazia , Waqas, Saad Ahmed, Ahmed, Raheel, Farhan, Kanza , Afridi, Abdullah , Ali, Muhammad Abdullah , Shahid, Iqra , Henna, Fathimathul , Waqas, Saad Ahmad

Mayo Clinic

Critical Pathways in Cardiology: A Journal of Evidence-Based Medicine | January 14, 2026 | Volume: 25 | Issue: 2 | Pages: e0415

10.1097/hpc.0000000000000415 | PMID 41533835 Get It

Despite advances in percutaneous coronary procedures, in-stent restenosis remains a significant challenge. Although sirolimus- and paclitaxel-coated balloons are promising alternatives, their comparative safety and efficacy remain uncertain. PubMed, Embase, and Cochrane databases were searched using relevant keywords from inception until August 2025. A total of 11 studies (7 randomized controlled trials and 4 observational cohort studies) were included, comprising 3633 participants overall. The primary outcomes assessed were target lesion revascularization and target lesion failure. Meanwhile, the Secondary outcomes included stent thrombosis, all-cause mortality, myocardial infarction, major adverse cardiovascular events, survival, binary restenosis, and angiographic endpoints (acute gain, diameter stenosis, in-segment late lumen loss, in-lesion late lumen loss, and in-segment minimal lumen diameter). Interstudy heterogeneity was assessed using I ² and X ² statistics ( I ²>50% = significant heterogeneity). Interstudy heterogeneity was low for most outcomes, including all primary clinical endpoints, with moderate heterogeneity observed only for select angiographic measures (notably in-segment late lumen loss and diameter stenosis). Statistical analysis was conducted using R software and RStudio (version 4.4.2), with a P value of < 0.05 indicating statistical significance. This meta-analysis examined studies that compared paclitaxel-coated balloon (PCB) versus standard balloon [sirolimus-coated balloon (SCB)] angioplasty. Regarding primary outcomes, there were no notable variations in target lesion failure [risk ratio (RR), 1.08, 95% CI, 0.90–1.29, P = 0.36] or target lesion revascularization (RR, 1.16, 95% CI, 0.98–1.37, P = 0.08). With all aggregated estimates being nonsignificant, secondary outcomes such as stent thrombosis, all-cause mortality, myocardial infarction, major adverse cardiovascular events, and survival were similar between groups. Angiographic endpoints revealed no discernible variations in late lumen loss (in-lesion and in-segment), acute gain, or diameter stenosis. Nonetheless, the SCB group’s minimal lumen diameter was significantly smaller than that of the PCB group (MD, −0.08 mm, 95% CI, −0.14 to −0.01, P = 0.02). In treating coronary in-stent restenosis, SCB and PCBs show similar overall safety and effectiveness; lesion-specific angiographic variations indicate that customized selection may improve patient outcomes.
Alzheimer's disease polygenic risk in early‐ and late‐onset Alzheimer's disease
Pentchev, Julian V., Jackson, Trever, Khan, Naazneen , Rosewood, Thea , Huang, Yen‐Ning, Nho, Kwangslk, Saykin, Andrew J., Eloyan, Ani, Taurone, Alexander, Thangarajah, Maryanne, Riddle, Meghan, Salloway, Steven, Atri, Alireza, Honig, Lawrence S., Johnson, Erik C. B., Turner, Raymond Scott, Masdeu, Joseph C. , Foroud, Tatiana M., Clark, David, Hammers, Dustin B., Dage, Jeffrey L., Kirby, Kala, Ghetti, Bernardino, Newell, Kathy, Onyike, Chiadi U., Day, Gregory S., Graff‐Radford, Neill R., Murray, Melissa E., Jones, D. Richard, Jack, Clifford R., Vemuri, Prashanthi, Touroutoglou, Alexandra, Duara, Ranjan, Grant, Ian, Sha, Sharon, Wingo, Thomas S., Beckett, Laurel A., Rogalski, Emily J, Mendez, Mario F., Kramer, Joel, Joie, Renaud La, Grinberg, Lea T., Koeppe, Robert, Wolk, David A., Aisen, Paul, RAMAN, REMA , Toga, Arthur, Kukull, Walter A., Musiek, Erik, Womack, Kyle, Carrillo, Maria C., Rabinovici, Gil D., Dickerson, Bradford C., Apostolova, Liana G., Nudelman, Kelly N. H., Murray, Melissa E. , Carrillo, María C. , Turner, Raymond Scott , Rabinovici, Gil D. , Joie, Renaud La , Day, Gregory S. , Day, Gregory S , Murray, Melissa E , La Joie, Renaud , Rabinovici, Gil D , Huang, Yen‐Ning, Nho, Kwangsik T. , Saykin, Andrew J. , Eloyan, Ani , Taurone, Alexander, Riddle, Meghan , Salloway, Steve , Atri, Alireza , Honig, Lawrence S. , Johnson, Erik C. B. , Masdeu, Joseph C , Foroud, Tatiana , Clark, David, Hammers, Dustin B , Dage, Jeffrey L. , Ghetti, Bernardino , Newell, Kathy L. , Onyike, Chiadi U. , Graff‐Radford, Neill R. , Jones, David T. , Jack, Clifford R. , Vemuri, Prashanthi , Touroutoglou, Alexandra , Duara, Ranjan , Sha, Sharon J. , Beckett, Laurel , Rogalskı, Emily , Mendez, Mario F. , Kramer, Joel, Blazhenets, Ganna , Grinberg, Lea T. , Koeppe, Robert A. , Wolk, David A. , Aisen, Paul , Toga, Arthur W. , Kukull, Walter A. , Musiek, Erik , Dickerson, Bradford Clark , Apostolova, Liana G. , Nudelman, Kelly

Mayo Clinic

Alzheimer's & Dementia | January 14, 2026 | Volume: 22 | Issue: 1 | Pages: No page available

10.1002/alz.71066 | PMID 41532810 Get It

Abstract INTRODUCTION The genetic basis of sporadic early‐onset Alzheimer's disease (EOAD) remains largely unknown, prompting evaluation of late‐onset Alzheimer's disease (LOAD) polygenic risk in EOAD. METHODS A LOAD polygenic score (PGS) was calculated in the Longitudinal Early‐onset Alzheimer's Disease Study (LEADS) and Alzheimer's Disease Neuroimaging Initiative (ADNI) study and tested for associations with AD risk, cognitive performance, and imaging and fluid biomarkers. RESULTS Though PGS was elevated in LOAD and EOAD, it was not a significant predictor of EOAD adjusting for APOE ε4 carrier status and was not associated with age of EOAD onset ( p = 0.106) or with cognitive performance ( p = 0.417). In LEADS, greater LOAD PGS was associated with differences in neuroimaging and fluid biomarkers, including elevated synaptosomal‐associated protein 25 (SNAP‐25) ( p = 2.3 × 10 −5 ). DISCUSSION While LOAD polygenic risk contributed minimally to EOAD onset and cognitive dysfunction, PGS association with fluid biomarkers in LEADS suggests a role for LOAD polygenic risk in EOAD pathophysiology. Highlights LOAD PGSs were elevated in both LOAD and EOAD compared to controls; however, LOAD PGS did not significantly predict EOAD risk, age at onset, or cognitive performance independent of APOE ε4 in the LEADS. Higher LOAD PGS was associated with lower amyloid PET Centiloids (less brain amyloid deposition) as well as lower CSF biomarker Aβ42 in LEADS (proxy marker suggesting higher brain amyloid deposition) in LEADS; these contradictory findings support the need for larger studies to further investigate whether LOAD PGS is associated with increased amyloid deposition in EOAD. Higher LOAD PGS was also associated with higher levels of CSF synaptosomal‐associated protein 25 (SNAP‐25), a key component of the SNARE complex, suggesting that LOAD genetic factors may contribute to dysregulation of synaptic transmission and/or pathological protein aggregation in EOAD.
Phase 2 trial of CBX-12 for metastatic chemotherapy-refractory microsatellite stable colorectal cancer (ETCTN 10707).
Chadha, Bhawneet, Beumer, Jan Hendrik, Karlovich, Chris , Anderson, Larry D., Mo, Christiana , Allegra, Carmen J. , Chu, Edward, Chadha, Bhawneet , Kaufmann, Scott H. , Moon, Jee‐Young , Beumer, Jan Hendrik , Villaruz, Liza Cosca , Anderson, Larry D. , Kuang, Chaoyuan

Mayo Clinic

Journal of Clinical Oncology | January 12, 2026 | Volume: 44 | Issue: 2_suppl | Pages: No page available

10.1200/jco.2026.44.2_suppl.tps259 Get It

TPS259 Background: Despite currently approved therapies, most patients with metastatic colorectal cancer (mCRC) progress through all approved treatments and eventually succumb to their disease. Thus, novel therapies for chemotherapy-refractory mCRC are desperately needed. Inhibition of the DNA unwinding enzyme TOP1 is a well-characterized and clinically successful treatment strategy for mCRC. CBX-12 is a novel peptide-drug conjugate comprised of an exatecan warhead linked to a pH-Low Insertion Peptide (pHLIP). The principle behind this targeting mechanism is based on the Warburg effect, in which tumors establish a low pH extracellular environment. The pHLIP moiety of CBX-12 preferentially forms a unidirectional, transmembrane alpha helix in a low-pH extracellular environment. Thus, CBX-12 delivers its exatecan cytotoxic warhead preferentially into tumor cells. In mouse xenograft models, CBX-12 inhibited the HCT116 CRC xenograft model more potently than an equimolar dose of free exatecan. The phase 1 study of CBX-12 reported cytopenias as the predominant AEs and confirmed responses in several solid tumors including mCRC. Methods: This is a single-arm, phase 2 trial, with a Simon 2-stage design assessing CBX-12 for the treatment of chemotherapy-refractory mCRC. The primary objective is efficacy determined by RECIST v1.1 response rate. Secondary and exploratory objectives include evaluating the PK and PD as well as the progression-free survival (PFS) on CBX-12. Key inclusion criteria include: age ≥18 years, ECOG performance status ≤1, histologically or cytologically confirmed mCRC that is MSS/pMMR based on CLIA-approved testing, and progression on 2 or more lines of chemotherapy. This design requires 17 patients for stage 1, with termination if 1 or fewer objective responses are seen out of 17. If 2 or more patients out of 17 responds, then an additional 18 patients will be enrolled for stage 2. If 5 out of the total of 35 patients (14%) respond, then the trial would be declared successful. Correlative studies will include tumor plus peripheral blood PK to evaluate effectiveness of CBX-12 tumor targeting, ctDNA, and several tumor PD markers including TOP1-DNA trapping, SLFN11 expression, DNA damage, and apoptosis. The trial opened to enrollment on 8/21/25. Clinical trial information: NCT06730100 .
P-1393. Tuberculosis Awareness and Misconceptions in Asian American and Pacific Islander Communities
Zhang, Kevin M, Razak, Noah, Alibin, Eloy, Santos, Nicole Delos, Man, Xuan, Hoang, Mai Vi, Zhang, David, Seto, Edward, Man, Xuan, Palraj, Raj

Mayo Clinic

Open Forum Infectious Diseases | January 12, 2026 | Volume: 13 | Issue: Supplement_1 | Pages: No page available

10.1093/ofid/ofaf695.1580 Get It

Abstract Background Stigma associated with tuberculosis (TB) and TB diagnosis is a major social factor in delay of diagnosis and non-adherence to TB treatment among Asian American and Pacific Islander (AAPI) populations. Main sources of stigma include misconceptions regarding TB transmission and lack of knowledge about symptoms or treatment.Figure 1.Respondent demographicsBreakdown of respondent demographics by age, gender, and AAPI subgroup.Figure 2.Demographic breakdown of TB awarenessTB awareness by AAPI subgroup, age, and gender. Methods A cross-sectional survey of 666 AAPI individuals analyzed TB symptom recognition, transmission misconceptions, and awareness in two AAPI community centers. Data were segmented by AAPI subgroup, metropolitan area (Seattle/Tacoma vs. Las Vegas), age, and gender.Figure 3.TB transmission beliefs.Figure 4.TB treatment, curability, and latent TB infection awareness. Results Overall, 76.6% of respondents reported TB awareness, varying by AAPI subgroup. Awareness was highest among Korean (95%) and Filipino (91%) participants, and lowest among Vietnamese (52%) and Cambodian (50%) respondents. Regionally, TB awareness was similar between Tacoma (76%) and Las Vegas (79%). Age and gender significantly impacted awareness. Respondents under 18 had the lowest TB awareness (59%), while those aged 18-34 had the highest (84%). Females reported higher TB awareness (79%) and symptom recognition (61%) than males (74% and 46%, respectively). Symptom knowledge varied. 55% were aware of TB symptoms, but only 16% were able to recognize five common TB symptoms. Misconceptions about transmission also persisted broadly. Out of the 71% of respondents who were aware that TB is transmissible, many incorrectly believed TB spread via shaking hands (35%), sharing food/drinks (50%), or touching items in public areas (37%). The 45-64 and 65+ age groups were most prone to misconceptions about transmission. While 72% of respondents were aware that TB could be treated, only 57% knew TB could be cured. 30% of respondents were aware of latent TB infection. Conclusion Significant disparities in TB awareness exist in AAPI communities. Females demonstrated greater TB awareness perhaps due to cultural differences (“caretaker role”), while TB transmission misconceptions were prevalent among older individuals. Limited knowledge on LTBI and TB treatment represent significant barriers to effective TB control. Tailored educational efforts will be required to improve TB awareness and reduce misconceptions within AAPI communities. Disclosures All Authors: No reported disclosures
2025 International Consensus Meeting on Musculoskeletal Infection: Summary From the Biofilm Workgroup on Biofilm Formation, Persistence, and Host‐Environment Interactions
Muthukrishnan, Gowrishankar , Coraça‐Huber, Débora C., Abbaszadeh, Ahmad , Abedi, Armita A., Abuhussein, Ezzuddin , Bingham, Joshua S. , Cichos, Kyle H. , Drago, L., Hamilton, John , Hickok, Noreen J., Iannotti, Ferdinando , Jensen, Louise Kruse, Li, Bingyun , Manzary, Mojieb, Moriarty, T. Fintan, McDonald, Katya , Nishitani, K., Norton, Nicholas, Oral, Ebru, Parvizi, Javad M., Raafat, Dina, Saeed, Kordo B. A., Sallai, Imre , Em, Schwarz, Siverino, Claudia , Tate, J.C. , Trobos, Margarita , Tubbs, Andie R., Hamilton, John L. , Saeed, Kordo , Abedi, Armita Armina , Bingham, Joshua S , Drago, Lorenzo , Hickok, Noreen J , Iannotti, Ferdinando , Moriarty, T Fintan , McDonald, Katya , Schwarz, Edward M , Abedi, Armita Armina , Coraça-Huber, Débora Cristina , Atkins, Gerald J. , Coenye, Tom , Jennings, Jessica Amber , Jensen, Louise Kruse , Nishitani, Kohei, Norton, Nicholas , Oral, Ebru , Parvizi, Javad , Raafat, Dina , Sekar, Amita

Mayo Clinic

Journal of Orthopaedic Research | January 9, 2026 | Volume: 44 | Issue: 1 | Pages: No page available

10.1002/jor.70130 | PMID 41506787 Get It

ABSTRACT Musculoskeletal infection (MSKI) remains a major problem after trauma and elective orthopedic surgery. Chronic MSKI is related to the formation of biofilm, which impairs diagnosis and effective treatments. Therefore, to understand and communicate global standards and best practices, the 2025 International Consensus Meeting (ICM) on MSKI created a Biofilm Section to address crucial aspects of biofilm biology pertaining to its mechanisms of drug resistance and immune evasion, and potential approaches to overcome them. This featured a 2‐year process, with final voting and discussion on May 8–10, 2025, in Istanbul, Turkey. This Consensus Article is the effort of the Biofilm Basic Mechanisms Workgroup, which interpreted the results on ICM questions related to (1) the infectious microenvironment; (2) appropriate inocula in preclinical research; (3) biofilm behavior in infected tissues; and (4) synergy within biofilms and with other comorbidities. Collectively, we find that this field has the necessary research tools to discover the pathophysiology of orthopedic implant‐associated biofilm development and maturation, perform clinically relevant studies in animal models, and elucidate mechanisms that allow opportunistic infections in compromised tissues and patients with other health issues.
Diagnostic AI model deployment in neurosurgery: lessons learned
Bernstein, Ross, Caron, Gabriel , Shin, Jimin, Zamora, Reynaldo, Ahn, Edward S., Bookland, Markus J. , Hersh, David S. , Martin, Jonathan E. , Ahn, Edward S.

Mayo Clinic

Journal of Neurosurgery: Pediatrics | January 8, 2026 | Volume: 37 | Issue: 3 | Pages: 262-268

10.3171/2025.9.peds25115 | PMID 41569781 Get It